DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 197 filers reported holding DENALI THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $9,585,704 | +28.1% | 324,829 | 0.0% | 0.38% | +31.6% |
| Q1 2023 | $7,484,060 | -1.2% | 324,829 | +19.2% | 0.28% | -0.3% |
| Q4 2022 | $7,578,781 | +11.0% | 272,520 | +22.5% | 0.29% | +2.5% |
| Q3 2022 | $6,826,000 | +4.3% | 222,420 | 0.0% | 0.28% | +8.6% |
| Q2 2022 | $6,546,000 | -8.5% | 222,420 | 0.0% | 0.26% | +2.4% |
| Q1 2022 | $7,155,000 | -27.9% | 222,420 | 0.0% | 0.25% | -21.3% |
| Q4 2021 | $9,920,000 | -11.6% | 222,420 | 0.0% | 0.32% | -11.6% |
| Q3 2021 | $11,221,000 | -4.7% | 222,420 | +48.2% | 0.36% | -5.7% |
| Q2 2021 | $11,773,000 | +37.4% | 150,086 | 0.0% | 0.38% | +29.8% |
| Q1 2021 | $8,570,000 | +41.4% | 150,086 | +107.5% | 0.30% | +38.5% |
| Q4 2020 | $6,059,000 | +1246.4% | 72,333 | +273.4% | 0.21% | +1083.3% |
| Q1 2019 | $450,000 | – | 19,372 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |